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Peripheral nerve injury remains a clinical challenge with severe physiological and functional consequences. Despite the existence of
multiple possible therapeutic approaches, until now, there is no consensus regarding the advantages of each option or the best
methodology in promoting nerve regeneration. Regenerative medicine is a promise to overcome this medical limitation, and in
this work, chitosan nerve guide conduits and olfactory mucosa mesenchymal stem/stromal cells were applied in different
therapeutic combinations to promote regeneration in sciatic nerves after neurotmesis injury. Over 20 weeks, the intervened
animals were subjected to a regular functional assessment (determination of motor performance, nociception, and sciatic
indexes), and after this period, they were evaluated kinematically and the sciatic nerves and cranial tibial muscles were evaluated
stereologically and histomorphometrically, respectively. The results obtained allowed confirming the beneficial effects of using
these therapeutic approaches. The use of chitosan NGCs and cells resulted in better motor performance, better sciatic indexes,
and lower gait dysfunction after 20 weeks. The use of only NGGs demonstrated better nociceptive recoveries. The stereological
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evaluation of the sciatic nerve revealed identical values in the different parameters for all therapeutic groups. In the muscle
histomorphometric evaluation, the groups treated with NGCs and cells showed results close to those of the group that received
traditional sutures, the one with the best final values. The therapeutic combinations studied show promising outcomes and should be
the target of new future works to overcome some irregularities found in the results and establish the combination of nerve guidance
conduits and olfactory mucosa mesenchymal stem/stromal cells as viable options in the treatment of peripheral nerves after injury.
1. Introduction
Peripheral nerve fibers are extremely fragile and sensitive
structures, susceptible to being easily damaged by crushing,
compression, or transection traumas [1]. Due to their high
prevalence, peripheral nerve injuries (PNI) are one of the
most important medical problems among traumatic hospital
patients. The injury of a peripheral nerve essentially affects
motor and sensory activity, interrupting the connection
between the central nervous system and the target organs
and muscles in the respective body region. In the long run,
these injuries lead to behavioral changes, mobility difficulties,
changes in consciousness and spatial perception, and loss of
cutaneous and joint sensitivity and culminate in lifelong dis-
abilities [2, 3]. These injuries are hard to standardize and
treat essentially due to the wide variations that can occur
regarding the type, location, severity, and complexity. Over
the years, different medical and surgical approaches have
been developed to treat PNI, but despite this, it has not yet
been possible to establish the ideal and transversal treatment
for all types of injuries [4]. It is known that the future of PNI
treatment will involve the use of multifactorial treatments to
promote sensory and motor recovery, and the maintenance
of neuromuscular junctions to stimulate the reinnervation
of target muscles and organs after periods of denervation is
the primary objective.
To standardize PNI, nerve injuries have been classified at
different levels depending on their severity, functional conse-
quences, and prognosis. This classification scheme facilitates
not only the determination of the pathophysiological phe-
nomenon associated with the injury but also the establish-
ment of the ideal treatment. The commonly applied PNI
classification is based on that established by the combined
efforts of Seddon and Sunderland [5, 6]. Seddon established
3 levels of PNI based on the degree of demyelination, the type
of axonal injury, and the degree of alteration of the nerve
connective tissue (endoneurium, perineurium, and epineu-
rium): neuropraxia, axonotmesis, and neurotmesis [5]. Later,
Sunderland expanded the PNI severity degrees to 5, with the
first degree corresponding to neuropraxia, the fifth corre-
sponding to neurotmesis, and the three intermediates deriv-
ing from axonotmesis, based on the involvement of the
different connective tissue envelopments [6]. Despite the
creation of this classification method, the difficulty in fitting
all types of injuries into these categories later led Mackin-
non to introduce an additional injury degree, basically a
mixed injury, probably the most common in real clinical
situations [7, 8].
After the occurrence of the PNI, two successive events of
nerve degeneration and regeneration occur [4, 9], and this
complex process involves the deletion of the inflammatory
process, the production and release of neurotrophic factors,
the stimulation of axonal regrowth, and the survival of neu-
rons. Schwann cells also play an essential role during the
regenerative phase of Wallerian degeneration, dividing and
proliferating to form Büngner bands that not only produce
neurotrophic and tissue adhesion factors but also guide axo-
nal regrowth and promote regeneration of myelin sheaths
[10]. However, all these regenerative phenomena are slow
due to their complexity, which leads to excessively prolonged
denervation periods in the target organs and muscles, which
often culminate in functional losses and irreversible neuro-
genic muscle inflammation and atrophy [11]. Thus, without
prompt interventions and effective surgical and therapeutic
approaches, PNI remains an intricate clinical challenge.
In neurotmesis injuries, the most serious ones, whenever
a good vascular bed is observed and an approximation of
nerve endings without tension is possible, the application of
end-to-end (EtE) sutures remains the treatment of choice
[12]. When this technique cannot be applied, transplantation
of autologous nerves to avoid rejection in the recipient is the
gold standard technique, although also associated with sev-
eral disadvantages: donor site morbidity and additional loss
of function, difficulties in finding sources of nerves matching
in size and characteristics, and performance of additional
incisions [13]. The use of nerve guidance conduits (NGCs)
has begun to be explored as a way to guide the regeneration
of axons towards the distal nerve top, avoiding the occur-
rence of common misdirecting phenomena, severe inflam-
matory reactions, and fibrosis. Different types of material
have already been tested for the production of NGCs, from
nonabsorbable materials to biodegradable ones. It is cur-
rently accepted that these materials should constitute a
completely degradable matrix, which positively influences
the regenerative phenomena without their biodegradation
process having negative local or systemic effects [14]. Despite
this, no material has yet been established that has all the
desirable characteristics and undoubtedly promotes effective
nerve regeneration.
Chitosan is one of the materials that has been studied and
is particularly advantageous because of its natural origin (chi-
tin in the shell of arthropods and cell membranes of fungi,
yeasts, and other microorganisms) [15], being completely
bioabsorbed and not producing toxic metabolites that inter-
fere with the regenerative process. In addition, chitosan
promotes cell adhesion and maintenance of cell and tissue
viability, has antimicrobial characteristics, and can be easily
modified chemically and enzymatically to release cytokines,
antibiotics, and components of the extracellular matrix
(ECM) in a controlled manner [4]. Preclinical studies carried
out with this material have shown that chitosan promotes
axonal regeneration, improves functional recovery, and
prevents the occurrence of extensive scarring and the devel-
opment of neuromas [16]. The number of studies in which
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chitosan-based NGCs were used is small, and as such there is
little data on the functional outcomes associated with their
application. Some studies using a chitosan-polyglycolic acid
combination demonstrated good motor and sensory recover-
ies when NGCs were used to bridge long-distance defects of
the median nerve [17, 18]. In 2014, a commercial NGC was
launched to the market, consisting purely of chitosan, and
called Reaxon® Nerve Guide (Medovent GmbH (Mainz,
Germany)). Developed in accordance with the international
standard DIN EN ISO 13485 [19], Reaxon® was initially
launched as 30mm long NGCs with 5 internal diameter
options to adapt to different therapeutic needs. Among the
most important characteristics of these NGCs, their high
flexibility and resistance to collapse, nonadherent surface,
malleability, and transparency that facilitate the insertion of
nerve tops and the application of sutures stand out. In addi-
tion, Reaxon® has a positively charged internal surface that
can interact with negatively charged cells and molecules,
allowing their combined action in promoting nerve regener-
ation. In this way, Reaxon® can be applied in tubulization
techniques after lesions of neurotmesis, bridging long gaps
through direct sutures between the nerve tops and the bioma-
terial, but also protecting the nerve tops connected through
tension-free EtE sutures [20, 21].
Olfactory mucosa mesenchymal stem/stromal cells (OM-
MSCs) are mesenchymal stem cells (MSCs) whose niche is in
the lamina propria of the olfactory mucosa. With ectodermal
origin, these cells express neural cell-related genes [22, 23]
and have been adequately identified and isolated in different
species [22–28]. Studies that focus on OM-MSCs are still few
but have already shown that these cells have the minimum
characteristics necessary for their characterization as MSCs
[29]: plastic adherence in culture with the formation of
fibroblastic-like colonies, capacity for tridifferentiation, and
expression of specific surface markers with no expression of
hematopoietic markers [22, 23]. Furthermore, these cells
are also capable of following myogenic [30] and neurogenic
differentiation [23, 30], and their conditioned medium is able
to promote the proliferation of glial cells and activation of
myelination in vitro [31]. Among the most important charac-
teristics of OM-MSCs are their distribution in several areas of
the nasal cavity that facilitates the collection in large and
small animal models, both through antemortem and
postmortem protocols, their origin in the neural crest, high
versatility, chromosomal stability, and the ability to maintain
self-renewal capacity over long periods of culture without
changes associated with the donor’s age [23, 32–34]. In
in vivo studies, OM-MSCs were mostly applied in works
associated with spinal cord trauma [35–37], degenerative dis-
eases of the central nervous system [38, 39], lesions of the
vestibulocochlear nerve [40–42], and lesions of the hippo-
campus [43, 44]. The studies in which these cells are applied
to promote peripheral nerve regeneration after PNI are even
more scarce, but the application of OM-MSCs in combina-
tion with a biphasic laminin and collagen-functionalized
hyaluronic acid NGC has shown better outcomes than the
use of the biomaterial alone [45].
ECM is the network of extracellular components whose
function is to provide biochemical and structural support to
cells, mainly consisting of macromolecules such as enzymes,
glycoproteins, collagen, fibronectin, and laminin [46]. ECM
is a fundamental component in the functional behavior
of MSCs, since in vivo those are included in a three-
dimensional microenvironment that interacts with neigh-
boring tissues and responds to different types of signals,
mediating cell attachment and migration [47, 48]. Hydro-
gels can be used to mimic the function of ECM in order
to facilitate the formation and maturation of tissues in
three-dimensional structures, both in vitro and in vivo
[49]. Matrigel® is a gelatinous mixture of proteins, soluble
and sterile, extracted from the basement membrane proteins
derived from Engelbreth-Holm-Swarm mouse sarcomas and
can be used as a basement membrane matrix for MSCs [50].
Its main component is laminin, also having collagen IV,
proteoglycans, heparan sulfate, and entactin/nidogen in its
constitution. Furthermore, it is also rich in several growth
and proregenerative factors such as epidermal growth factor,
insulin-like growth factor, fibroblast growth factor, TGF-β,
and tissue plasminogen activator [51, 52]. At body tempera-
ture, 37°C, Matrigel® gels and forms a structure identical to
three-dimensional ECM, supporting cell adhesion and
differentiation and providing the ideal environment to
promote in vivo regeneration of different tissues. Effectively,
the use of Matrigel® promotes attachment and differentiation
of neurons [53, 54] and supports in vivo peripheral nerve
regeneration [55–58].
The combined use of MSCs with NGCs [59] and the
combination of MSCs with Matrigel® [57] are two of the
potential approaches to alter the paradigm associated with
the stimulation of peripheral nerve regeneration after PNI.
In this work, we tested the hypothesis that the combined
use of Reaxon® NGCs and OM-MSCs suspended in Matri-
gel® may enhance the histomorphometric and functional
regeneration of the rat’s sciatic nerve after neurotmesis.
2. Materials and Methods
2.1. Preparation and Characterization of OM-MSCs
2.1.1. Harvesting and Cell Culture.OM-MSCs were harvested
from the rat’s olfactory mucosa and maintained in culture as
previously described [23, 60]. Briefly, OM-MSCs were
collected from the rat’s olfactory mucosa, nasal septum, and
ethmoturbinates [60], isolated through a mixed method of
enzymatic digestion and explant, expanded, and maintained
in culture in standard conditions (37°C, 5% CO2 and humid-
ified atmosphere) using a basal culture medium consisting
of Basal Medium (DMEM/F12+GlutaMAX™ supplement,
Gibco®) supplemented with 10% certified fetal bovine
serum (One Shot Fetal Bovine Serum, Gibco®), 1.5%
penicillin-streptomycin (Sigma-Aldrich®), and 1.5% ampho-
tericin B (Sigma-Aldrich®). Cells were cryopreserved using
basal culture medium and 10% dimethyl sulfoxide (DMSO)
(Sigma-Aldrich®) in cryovials with at least 1 × 106 cells.
Before being used in the different assays, cells were thawed
in a water bath (37°C), collected, centrifuged, resuspended
in basal culture medium, counted, cultured, and maintained
under standard conditions. For each assay, the culture
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medium was eliminated, the culture was washed with PBS,
and the cells were detached using 0.25% Trypsin-EDTA
(Sigma-Aldrich®) (3–5min incubation under standard
conditions). After centrifugation (1600 rpm, 10min) and
elimination of the supernatant, the number of cells and their
viability were determined by a Trypan blue (Invitrogen™)
exclusion cell assay using an automatic counter (Countess II
FL Automated Cell Counter, Thermo Fisher Scientific®) [23].
2.1.2. Reverse Transcriptase Polymerase Chain Reaction (RT-
PCR). To identify the expression of specific genes by OM-
MSCs undifferentiated and after neurogenic differentiation,
RT-PCR was performed.
(1) RNA Isolation and cDNA Synthesis. RNA isolation was
carried out on OM-MSCs in their undifferentiated state and
after the induction of neurogenic differentiation. Neurogenic
differentiation was achieved as previously described [23]. For
RNA isolation, the Aurum™ Total RNA Mini Kit (Bio-Rad
Laboratories®) was used, following the manufacturer’s
instructions. Briefly, a 2 × 106 cell pellet of both P6 differen-
tiated (72 h of differentiation) and undifferentiated OM-
MSCs was lysed with a lysis solution, followed by DNA
removal with a DNAase I enzyme and elution with 80μl of
an elution solution. RNA was maintained at -80°C.
Prior to cDNA synthesis, the purity and amount of the iso-
lated RNA were determined using a UV-spectrophotometry
technique and measuring the A260/A280 (to identify protein
contamination) and A260/A230 (to identify phenol, polysaccha-
rides, and/or chaotropic salt contaminations) absorbances
on a NanoDrop™ One Microvolume UV-Vis Spectropho-
tometer (Thermo Scientific™). Purity values considered
adequate include the interval 2-2.2 to A260/A280 and 1.8-
2.2 to A260/A230 [61].
The first cDNA strands were synthesized from 4μl of
total RNA in 20μl final volume, following the manufacturer’s
instructions for the iScript™ cDNA Synthesis Kit (Bio-Rad
Laboratories®). The complete reaction mix was then incu-
bated in the thermal cycler (T100™ Thermal Cycler, Bio-
Rad Laboratories®) using time and temperature guidelines
indicated by the manufacturer’s instructions.
(2) Quantitative RT-PCR Assay. The RT-PCR assay was con-
ducted using the CFX96 Touch™ Real-Time PCR Detection
System (Bio-Rad Laboratories®) under standard PCR condi-
tions and using iTaq™ Universal SYBR Green Supermix
(Bio-Rad Laboratories®) according to the manufacturer’s
instructions. 22 genes associated with markers of neuroglial
expression were searched, including specific markers of
immature and mature neurons and markers of glial cells at
different stages of maturation. Markers associated with glial
cells include Aldh1l1, CD40, Cdh2, Cspg4, GAP43, GFAP,
MPZ, NCAM, Nes, Ocln, Olig3, Sox10, and Sox2; neuron-
associated markers include Ascl1, Dcx, MAP2, NueroD1,
Rbfox3, Syn, Cdk5r1, Cript, Tubb3, and again GAP43. β-
Actin was used as a housekeeping gene. A 96-well plate
(PrimePCR Custom Plate 96 Well, Bio-Rad Laboratories®)
was prepared with the 22 predesigned primers for the genes
to be identified, in order to allow the identification of their
genetic expression (Table S1 shows the list of genes under
study with the respective amplicon context sequences,
ensemble gene ID, and PCR product lengths). Plates were
read in a real-time PCR detection system. Two pairs of
primers targeting the genes were used to analyze their
expression in undifferentiated and differentiated OM-
MSCs. Plates containing the mix targeting the 22 genes
were exposed to the temperature cycles indicated by the
manufacturers. Once the RT-PCR was finished, the gene
expression was analyzed and interpreted. To confirm the
specificity of the product, the melting curves were also
analyzed.
The values of threshold cycle (Ct) were interpreted as fol-
lows: Ct < 29 indicates strong positive reactions and abun-
dant targeted nucleic acid in the sample, 30 < Ct < 39
indicates positive reactions and moderate amounts of tar-
geted nucleic acid, and Ct > 39 appears in weak reactions
with minimum targeted nucleic acid values or in environ-
mental contaminations.
For the two groups of cells, the ΔCt value was calculated
through the formula ΔCt = Cttarget gene − Cthousekeeping gene.
Fold differences between the two groups were calculated
using the standard ΔΔCt through the formula ΔΔCt =
ΔΔCtdifferentiated − ΔΔCtundifferentiated. The relative quantifica-
tion (RQ) was determined by the formula RQ = 2−ðΔΔCtÞ.
Genes with RQ values < 0:5 were considered downregulated,
and those with RQ values > 2 were considered upregulated.
2.1.3. Immunohistochemical Analysis. Early passage (P6)
OM-MSCs were submitted to immunohistochemical analysis
to detect specific antigens associated with neurogenic differ-
entiation. In one plate, OM-MSCs were maintained in their
undifferentiated state and in another; in the same passage,
the cells were subjected to neurogenic differentiation as pre-
viously described [23]. In undifferentiated cells, culture was
maintained until a confluence of 70–80% was reached; cells
submitted to differentiation were maintained for 72 hours
in the neurogenic differentiation medium. For both cases,
the cells were detached using 0.25% Trypsin-EDTA solution
and kept in a paraffin cytoblock (Surein® Preserve Cell solu-
tion®, Cytoglobe GmbH®). Subsequently, sections were cut at
2μm, subjected to deparaffinization, and dehydrated,
followed by an immunohistochemical analysis using a Novo-
link™ Polymer Detection Systems (Leica Biosystems®) kit,
according to the manufacturer’s instructions. Information
about the primary antibodies and antigen retrieval methods
used is depicted in Table 1. The antibodies were selected to
identify the presence of markers of neuronal (NeuN and
GAP43) and glial (GFAP) origin, complementary to the
results obtained by the RT-PCR technique.
Cellular immunoexpression was evaluated using an
Eclipse E600 microscope (Nikon®) and the software Imaging
Software NIS-Elements F Ver4.30.01 (Laboratory Imaging®),
with respective interpretation and photographic record. For
the different markers, immunoexpression was scored for
labeling intensity (0, negative; +, weak; ++, moderate;
and +++, strong). When distinct cytoplasm and nuclear
staining was recognized in at least 5% of the total cell
populations, immunoreactivity was considered positive.
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2.2. In Vitro Cytocompatibility Assessment. To determine the
compatibility between OM-MSCs and Reaxon® NGCs and
Matrigel® to be used in the in vivo assays, a PrestoBlue™
viability assay was carried out. Four groups were established:
(1) OM-MSCs seeded in contact with Reaxon® tubes and
with basal medium, (2) OM-MSCs seeded on Matrigel®
(Corning®) and with basal medium, (3) OM-MSCs seeded
with basal medium (positive control), and (4) OM-MSCs
seeded with basal medium supplemented with 10% DMSO
(negative control) instead of 10% FBS. In the first group,
Reaxon® NGCs were cut transversely to a suitable length
and then placed inside a row of wells on a 24-well plate. In
the second group, Matrigel® diluted in DMEM/F12 (1 : 1)
was applied to a row of wells on the 24-well plate to cover
its bottom, following the manufacturer’s instructions. In the
wells of all groups, OM-MSCs were seeded at a density of
6000 cells/cm2, with the addition of the medium considered.
Cell metabolic activity was assessed at 24 h, 72 h, 120 h, 168 h,
and 216h, always in quadruplicate for each group in each
time point. At each time point, the culture media were
replaced with fresh complete medium, with the addition of
10% (v/v) of 10x PrestoBlue™ cell viability reagent (Invitro-
gen, A13262). Unseeded control wells were used as blank
sets. Then, the plates were incubated for 1 hour under stan-
dard conditions. After this period, to identify supernatant
color reflecting cell viability variances, the supernatant from
each well was collected and transferred to a 96-well plate,
followed by the absorbance reading at 570nm (excitation
wavelength) and 595 nm (emission wavelength) by spectro-
photometry using a microplate photometer (Thermo Scien-
tific™ Multiskan™ FC). Absorbance reading from each well
was normalized to the emission wavelength, and the cor-
rected absorbance value was obtained by the subtraction of
the average of unseeded control wells to each experimental
well. After collecting the supernatant to be analyzed, the wells
were washed with PBS to remove the remains and residues of
PrestoBlue™ dye and a new fresh medium was added.
Between evaluations, the plates were kept in standard
conditions.
2.3. Scanning Electron Microscopy Analysis. After determin-
ing the cytocompatibility between OM-MSCs and Reaxon®,
a scanning electron microscopy (SEM) Analysis and
energy-dispersive X-ray spectroscopy (EDS) exams were per-
formed, using a high-resolution (Schottky) environmental
scanning electron microscope with X-ray microanalysis and
electron backscattered diffraction analysis: Quanta 400 FEG
ESEM/EDAX Genesis X4M, operating in a high vacuum
mode at an accelerating voltage of 15 kV SEM.
Reaxon® NGCs were cut transversely to fit the diameter
of a well in a 24-well plate and then cut longitudinally. Each
half-NGC was then placed inside a well. OM-MSCs were
seeded in a density of 6000/cm2 with basal culture medium
over the internal surface of the cut NGCs, remaining in cul-
ture for 216 hours, with medium changes every 2-3 days.
After this period, the wells were washed three times with
0.1M HEPES buffer (Merck®, PHG0001). The cells on the
inner surface of the NGCs were fixed with 2% buffered glu-
taraldehyde (Merck®, G7651) and kept in this solution over-
night. Then, the cells were washed in three cycles of five
minutes with 0.1M HEPES buffer, with gentle agitation.
The samples were then dehydrated in a graded series of eth-
anol (50%-70%-90%-99%), followed by chemical drying with
hexamethyldisilazane (HMDS) (Merck®, 440191) in ethanol
for 15 minutes and an incubation with HMDS alone for 15
minutes. Finally, after removing HDMS from all wells, the
plate was left overnight in the laminar flow chamber for total
evaporation. Before SEM and EDS, samples collected from
the wells were coated with gold/palladium by sputtering,
using the SPI Module Sputter Coater equipment.
2.4. In Vivo Assays
2.4.1. Animals. All steps involving animals were approved by
the Organism Responsible for Animal Welfare (ORBEA) of
the Abel Salazar Institute for Biomedical Sciences (ICBAS)
from the University of Porto (UP) (project 209/2017) and
by the Veterinary Authorities of Portugal (DGAV) (project
DGAV: 2018-07-11014510), always in conformity with the
Directive 2010/63/EU of the European Parliament and the
Portuguese DL 113/2013, following the OECD Guidance
Document on the Recognition, Assessment and Use of Clin-
ical Signs as Humane Endpoints for Experimental Animals
Used in Safety Evaluation (2000). Additionally, all measures
were taken to avoid any pain and discomfort and to guaran-
tee animal welfare, considering all humane endpoints for
animal suffering and distress.
Thirty rats (Rattus norvegicus), Sasco Sprague-Dawley
Breed, 8 to 9 weeks old, and 250-300 g BW (Charles River,
Barcelona, Spain), were used in this work. Only males were
used, to avoid hormonal influences resulting from the differ-
ent reproductive phases observed in females. Animals were
housed in rooms with controlled temperature and humidity,
2 to 3 animals per cage, with 12-12 h light/dark cycles. The
cages were equipped with environmental enrichment, and
the normal physiological activities were allowed, under stan-
dard laboratorial conditions. Chow and water were always
available ad libitum. After reception, animals were kept
under acclimatization for two weeks.
2.4.2. Experimental Design. Rats submitted to a neurotmesis
lesion of the sciatic nerve were divided into six experimental
Table 1: List of antibodies investigated, dilutions, and antigen retrieval methods applied in the immunohistochemical analysis.
Antibody Clonality Manufacturer Dilution Antigen retrieval
GFAP Polyclonal Proteintech® 1/1000 Water bath/20min
NeuN Polyclonal Proteintech® 1/800 Water bath/20min
GAP43 Polyclonal Proteintech® 1/500 Water bath/20min
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therapeutic groups (Figure 1): group 1—uninjured control
(UC) (n = 30), group 2—EtE (n = 5), group 3—suture of the
nerve ends to the Reaxon® NGC (R) (n = 6), group 4—EtE
and wrapping with Reaxon® NGC (EtER) (n = 6), group
5—suture of the nerve ends to the Reaxon® NGC and admin-
istration of OM-MSCs suspended in Matrigel® (1 × 106 cells
suspended in 300μl of Matrigel® diluted in basal culture
medium (1 : 1)) (ROM) (n = 7), and group 6—EtE, wrapping
with Reaxon® NGC, and administration of OM-MSCs sus-
pended in Matrigel® (EtEROM) (1 × 106 cells suspended in
300μl of Matrigel® diluted in basal culture medium (1 : 1))
(n = 6). Reaxon® NGCs with 2.1mm internal diameter and
15mm length were used. Nerve transection and repair were
performed on the right hind limb, and the contralateral limb
was used as the uninjured control. Primary outcomes
consisted of assessing motor, nociceptive, and behavioral
function and kinematic evaluation; secondary outcomes
included the determination of the mass of the cranial tibial
muscle (M. tibialis cranialis) and its histomorphometric
evaluation and also the stereological assessment of the sciatic
nerve after collection.
2.4.3. Surgical Procedures. The surgical techniques used in
this work were based on the protocols used and described
previously [62–64], and the specific procedures are below:
(1) Sciatic Nerve Repair Model. Animals were anesthetized
with xylazine/ketamine (Rompun®/Imalgene 1000®; 1.25mg/
9mg per 100g BW), administered intraperitoneally. Once
anesthetized, the rats were placed in left lateral decubitus
and the right limb was prepared for surgery (trichotomy and
asepsis). Surgeries were conducted under an M-650 operating
microscope (Leica Microsystems, Wetzlar, Germany). The
nerve was accessed through a skin incision initiated at the level
of the greater trochanter and extending distally to midhalf of
the thigh. After careful subcutaneous debridement, a separa-
tion of the vastus lateralis and biceps femorismuscles was per-
formed to expose the sciatic nerve. With the muscles kept
apart by a soft tissue retractor, the sciatic nerve was carefully
separated from neighboring tissues and immobilized, followed
by a complete transection (neurotmesis) with a straight micro-
surgical scissor immediately before the branching site into
common peroneal and tibial nerves.
With the contralateral nerve being considered the control
and being part of the UC group, the intervened nerves were
subjected to the therapeutic approaches considered. In the
EtE group, the nervous tops were coaptized, ensuring ana-
tomical alignment and orientation and maintaining a mini-
mum gap between the nerve ends. To ensure this position
and to avoid misalignments and rotations, simple inter-
rupted epineural microsutures between the two nervous tops
(2-4 sutures) using 7/0 monofilament nylon were applied. In
group R, about 3mm of the nerve tops was inserted into the
Reaxon® NGCs and fixed to the biomaterial as aligned and
oriented as possible through epineural microsutures, using
7/0 monofilament nylon (2-4 sutures) and leaving a gap of
approximately 10mm between the two nerve ends. In the
EtER group, tension-free suture was applied as described.
Then, Reaxon® NGCs, with a longitudinal incision, were
placed wrapping the nerve and the suture site, with the nerve
and NGC being properly accommodated among the muscle
mass to avoid displacement of the biomaterial. In the ROM
group, the nerve tops were inserted into Reaxon® NGC and
sutured as described. Then, OM-MSCs suspended in culture
medium and Matrigel® were injected inside the NGC to fill
its internal diameter. Finally, in the EtEROM group, the
application of tension-free suture and wrapping with
Reaxon® NGC was carried out as described, followed by the
filling of the internal diameter of the NGC with OM-MSCs
suspended in culture medium and Matrigel®. After the surgi-
cal intervention, the muscular, subcutaneous, and cutaneous
layers were closed with simple interrupted sutures with 4-0
absorbable material. To avoid autotomy, all animals received
a deterrent substance on the right paw. Anesthetic recovery












Figure 1: Experimental therapies applied to the sciatic nerve after neurotmesis injury. The applied NGCs are 15mm long and have an
internal diameter of 2.1mm.
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to the housing facilities after all animals had awakened and
returned to their normal behavior. After surgery, and for five
consecutive days, the animals were medicated with carprofen
(2-5mg/kg SC QD). Throughout the study period, animals
were frequently monitored and evaluated for signs of
autotomy, contractures, and the development of wounds
or infections.
2.4.4. Functional Assessment. After the surgical performance
of standardized neurotmesis injuries and application of ther-
apeutic approaches, a periodic functional evaluation was
carried out to determine the progression of the nervous
regenerative process. All animals were evaluated before sur-
gery (week 0) to establish the baseline of healthy behavior.
After neurotmesis, the animals were evaluated after one and
two weeks and thereafter every two weeks until week 20.
All tests of the functional assessment sessions were per-
formed by the same operator with experience in the applied
techniques to avoid interindividual variances, and efforts
were made to ensure a calm and stress-free environment so
as not to condition the observed results.
(1) Motor Performance. The extended postural thrust (EPT)
test was used to assess motor performance, as previously
described [62, 65]. To perform this test, the rat’s body is
wrapped in a soft cloth, keeping the head and hind limbs
exposed. Then, the animal is suspended over a digital weigh-
ing machine (model TM 560; Gibertini, Milan, Italy) and
lowered slowly towards it. It is important that the rat is able
to maintain visual contact with the weighing machine in
order to be able to anticipate contact and voluntarily extend
the hind limb. Contact with the weighing machine must be
made with the distal metatarsals and digits (Figure 2(a)).
The force applied during contact with the weighing machine
is measured in grams and recorded for both the healthy
(NEPT) and injured (EEPT) limbs. The registration is done
in triplicate, and the final value considered is the average of
the three weighing values. The EEPT and NEPT values are
then integrated into the following equation [66], in order to
determine the percentage of motor functional deficit:
%motor deficit = NEPT − EEPT
NEPT
× 100: ð1Þ
(2) Nociceptive Function. The withdrawal reflex latency
(WRL) test was used to assess the integrity of nociceptive
function [67]. As in the previous test, the animal is wrapped
in a soft cloth and suspended over a heating plate at 56°C
(model 35-D, IITC Life Science Instruments, Woodland Hill,
CA). The rat’s paw should be placed over the surface of the
heating plate, ensuring that the lateral aspect of the paw
innervated by the sciatic nerve intervened is the one that con-
tacts the plate [65]. WRL is defined as the time, in seconds,
that it takes for the animal to retract its hind limb after con-
tact of the corresponding paw with the surface of the plate.
This time is determined by averaging three measurements
for each limb, waiting two minutes between each measure-
ment to avoid sensitization phenomena. In the case of a
healthy nerve, the animal will retract the limb in 4.3 s or less.
12 s is considered the maximum limit of contact between the
paw and the heating plate, and if the animal does not retract
the limb in this period, the operator should move it away to
avoid injuries and burns to the tissues [68]. The animal’s
paw should be placed gently on the plate, since manual com-
pression can activate mechanoreceptors and cause the limb
to retract without nociceptive activation [69] (Figure 2(b)).
Similarly, it is important to remember that the medial aspect
of the plantar surface of the paw is innervated by the
saphenous nerve, branch of the femoral nerve, and as such
saphenous nerve collateral sprouting around the denervated
zone is possible. Therefore, it is important to ensure contact
of the paw’s lateral aspect against the heated surface to
guarantee truthful results [65].
(3) Walking Track Analysis. The assessment of the walking
pattern can be done by determining the sciatic functional
index (SFI). In this work, a video collection technique was
applied, adapting the techniques used in other groups using
ink footprint records [65]. The animal is placed inside a
transparent acrylic corridor, below which an image capture
system is placed. At the end of the corridor, a shelter is
installed to encourage the animal to walk in that direction.
The rat is placed at the beginning of the tunnel and stimu-
lated to move towards the shelter, allowing the registration
of the feet in contact with the floor of the corridor when pass-
ing over the recording system (Figure 2(c)). For each animal,
three records corresponding to three valid steps were consid-
ered, and a valid step is one in which paleness in the paw
limits and support points are observed, resulting from its
pressure against the floor of the corridor. The acquired
images were then analyzed using an image processing soft-
ware (Image-Pro Plus® 6, Media Cybernetics, Inc.), consider-
ing the calibration corresponding to the distance between the
floor of the corridor and the video capture device and allow-
ing the obtainment of the three measures considered for both
healthy and experimental paws: print length (PL), toe spread
distance between toes 1 and 5 (TS), and toe spread between
toes 2 and 4 (ITS) (Figure 2(d)). The mean values obtained
are then used in the following formulas (N stands for
“normal” and E stands for “experimental”):
Print lengh factor PLFð Þ = EPL −NPLNPL ,
Toe spread factor TSFð Þ = ETS −NTSNTS ,
Intermediate toe spread factor ITFð Þ = EIT −NITNIT : ð2Þ
The values collected are then introduced in the following
formula:
SFI = −38:3 ∗ PLFð Þ + 109:5 ∗ TSFð Þ + 13:3 ∗ ITFð Þ − 8:8:
ð3Þ
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SFI values are around 0 on healthy animals and close
to -100 on animals with a complete lesion in the sciatic
nerve [70].
The static sciatic index (SSI) is derived from SFI but
has the particularity of being determined in standing ani-








Figure 2: (a) Execution of the EPT test, with extension of the paw on the weighing machine to test motor performance. (b) Execution of the
WRL test, with positioning of the right paw on the heating plate to test nociception. (c) Determination of the SFI with video recording of the
animal’s paw in contact with the acrylic corridor during gait. (d) Analysis of the animal’s paw in contact with the acrylic corridor during gait,
with determination of the PL, TS, and ITS values. (e) Determination of SSI with photographic record of the animal’s paw in contact with the
acrylic box. EPT: extended postural thrust; WRL: withdrawal reflex latency; SFI: sciatic functional index; SSI: static sciatic index; PL: print
length; TS: toe spread; ITS: intermediate toe spread.
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measurement, the rat is placed inside a transparent acrylic
box, which in turn is placed inside the corridor. Thus, the
animal is stationary, with both limbs in contact with the
box floor, allowing the photographic capture through the
device placed immediately below (Figure 2(e)). The TS and
ITS values of both healthy and experimental limbs are care-
fully measured in triplicate as previously described, and the
mean values are integrated into the following formulas:
Toe spread factor TSFð Þ = ETS −NTSNTS ,
Intermediate toe spread factor ITFð Þ = EIT −NITNIT : ð4Þ
The SSI value is determined by the formula:
SSI = 108:44 ∗ TSFð Þ + 31:85 ∗ ITFð Þ − 5:49: ð5Þ
The SSI value is around -5 on healthy animals and around
-90 on animals with complete sciatic nerve lesions [70].
(4) Kinematic Analysis. Ankle kinematics during the gait
cycle were recorded at the end of the 20 weeks for the estab-
lished therapeutic groups and compared with the gait cycle
pattern of the UC group, whose values were obtained before
the induction of neurotmesis lesions. Motion capture was
collected with an optoelectronic system of 6 cameras (Opti-
Track Flex 3 model, NaturalPoint, Inc.) and the software
Motive (NaturalPoint, Inc.) operating at a 120Hz framerate.
Animals walked on an acrylic track with length, width, and
height of, respectively, 120, 12, and 15 cm (Figure 3(a)). After
trichotomy, three reflective markers with 2mm diameter
were attached to 3 bony prominences on the right hind limb
of the rat: the fifth metatarsal, the lateral malleolus, and the
lateral epicondyle. All markers were placed by the same oper-
ator to avoid interindividual variations. Two body segments
(foot and shank) were reconstructed using the Visual 3D
software, and the rat’s ankle angle (θ°) was determined using
the scalar product between the vector representing the foot
and the vector representing the shank (Figure 3(b)) during
the stance phase and swing phase considered in the rat gait
cycle [72]. With this model, positive and negative values for
the position of the ankle joint indicate dorsiflexion and plan-
tarflexion, respectively. All the gait variables were normalized
for 100% of the gait cycle, and for each cycle, the initial con-
tact and the toe-off instants were identified. The normalized
temporal parameters were averaged over all recorded trials.
2.4.5. Stereological and Histomorphometric Analysis
(1) Nerve Stereological Analysis. After the established 20
weeks of the study, animals were euthanized using general
anesthesia followed by lethal overdose with Eutasil®
(200mg/ml, 200mg/kg b.w., intraperitoneally). Once eutha-
nasia was confirmed, the injured sciatic nerves (10mm long
samples distal to the lesion site) and uninjured controls were
collected (Figure 4(a)) and adequately fixed for further ste-
reological evaluation through light and electron microscopy.
The access to the nerve to be collected was performed in the
same way as access to surgical intervention. After exposure of
the sciatic nerve, it was covered with fixation solution (2.5%
purified glutaraldehyde and 0.5% saccharose in 0.1M Soren-
sen phosphate buffer (pH7.4, 4°C)) in order to promote its
hardening and facilitate handling and collection. After exci-
sion, the 10mm long segment whose proximal portion was
properly identified was immersed in the same fixation solu-
tion and correctly aligned and oriented for 5 minutes to pre-
vent nerve tangling. Then, the segments were kept immersed
in the fixation solution for 6-8 hours, after which they were
washed thoroughly and immersed in 1.5% saccharose wash
solution in 0.1M Sorensen phosphate buffer (pH7.4) for 6-
12 h. The histological preparation and histomorphometric
evaluation were later performed according to the previously
described protocol [73], and the parameters total number
of fibers (N), fiber density (N/mm2), axon diameter (μ), fiber
diameter (μ), myelin thickness (M, μ), and cross-sectional
area (mm2) were considered, in addition to the ratios d/D








Figure 3: (a) Image capture set for kinematic analysis. At the end of the acrylic track, a shelter is placed to attract the animal, guaranteeing a
straight line during locomotion. (b) Anatomical positions for placement of the reflective markers on the hind limb of the rat, with the
respective ankle angle.
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(2) Histomorphometric Muscle Analysis. In parallel with the
collection of the sciatic nerves, the cranial tibial muscles were
also collected (Figure 4(b)) for further histomorphometric
assessment and determination of the neurogenic atrophy
degree. The collected muscles from both injured and healthy
limbs were weighed and then fixed with 4% buffered formal-
dehyde and processed for routine histopathological analysis
(haematoxylin and eosin (H&E)). From the midbelly region
of the muscle, consecutive sections (3μm thick) were
obtained, prepared, and stained, and low-magnification
images (100x) were obtained with a Nikon® microscope con-
nected to a Nikon® digital camera DXM1200. The images
obtained were processed using ImageJ© software (NIH),
through an unbiased sampling procedure. Individual fiber
measurements were obtained, and the muscle fiber area and
minimal Feret’s diameter (minimum distance of parallel tan-
gents at opposing borders of the muscle fiber) were calcu-
lated. Measurements were blindly and randomly obtained
from a minimum of 800 fibers for each group, by 2 indepen-
dent and experienced operators.
2.4.6. Statistical Analysis. Statistical analysis was performed
using the software GraphPad Prism version 6.00 for Win-
dows (GraphPad Software, La Jolla, California, USA). When
appropriate, data were expressed as mean ± SEM. Compari-
sons between groups were performed with an analysis
through a parametric test. A value of p < 0:05 is considered
statistically significant. Significance of the results is shown
according to p values by the symbol ∗: ∗ corresponds to
0:01 ≤ p < 0:05, ∗∗ to 0:001 ≤ p < 0:01, ∗∗∗ to 0:0001 ≤ p <
0:001, and ∗∗∗∗ to p < 0:0001.
For the kinematic analysis, in order to objectively quan-
tify the differences in the gait analysis, a statistical parametric
mapping (SPM) was used, a statistical approach that allows
hypothesis testing on kinematic and kinetic waveforms with-
out the need of a priori data reduction. SPM was used to ana-
lyze the ankle planar angle in gait trials, in a large cohort of
rat after neurotmesis. SPM unpaired t-tests were performed,
comparing the mean kinematic angle of each pattern to the
respective mean kinematic angle of the control group
(α = 0:05). All analyses were performed on retrospectively
collected data, using open-source SPM1d version M.0.4.7
(2019.11.27; http://www.spm1D.org) in MATLAB1.
3. Results
3.1. RT-PCR. Ct average values for each gene, ΔCt, ΔΔCt, and
RQ values can be seen in Table 2. The purity level assay using
the UV-spectrophotometry technique revealed that all RNA
samples were pure, allowing their use in the following stages.
The analysis of the melting curves revealed the presence of a
single peak in the curve of each gene, thus confirming the
amplification of a single amplicon. In undifferentiated cells,
the Cript and Cspg4 genes showed Ct < 29. All other genes,
excluding Olig3, have Ct values between 29 and 39, indicat-
ing positive reaction and the presence of the target nucleic
acid in the sample in moderate amounts. The Dcx, Rbfox3,
and Syp genes were not identified in these cells, as well as
the MPZ gene that was not identified in any of the cell
groups. In differentiated cells, only Cript showed Ct < 29,
with Ascl1, Dcx, and GAP43 with values > 39 and all other
genes identified with positive reaction and in moderate
amounts in the samples. The Ocln and Olig3 genes, identified
in the undifferentiated cells, were not found in the differenti-
ated ones. Conversely, the Dcx, Rbfox3, and Syp genes were
identified in the cells only after neurogenic induction.
Comparing the two passages, changes in fold expression
of the genes were observed. In the genes identified in the
two types of cells, upregulation was observed in practically
all of them in neurologically differentiated cells compared
to undifferentiated ones, excluding Cspg4, GAP43, and Neu-
rod1 that maintained normal expression. No downregulated
genes were observed, and in genes that were not identified in
the two cell types, it was not possible to determine the relative
expression. Statistically significant differences were identified
between ΔCt values of the genes Aldh1l1, Cd40, Cdh2,
Cdk5r1, Map2, Ncam, Sox2, and Tubb3 (Figure 5).
3.2. Immunohistochemical Analysis. The results of the immu-
nohistochemistry evaluation can be analyzed in Figure 6.
(a) (b)
Figure 4: (a) Exposure of the sciatic nerve of the ROM therapeutic group, 20 weeks after surgery. It is possible to observe the regenerated
nerve filling all the lumen of the NGC, with the two nerve tops connected. (b) Comparison of the mass of cranial tibial muscles of the
healthy limb (left) and subject to neurotmesis (right) after collection at 20 weeks.
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After neurogenic differentiation, OM-MSCs showed immu-
noreactivity for GFAP (+++), NeuN (+), and GAP43 (++).
In undifferentiated cells, only immunoreactivity for GFAP
(+) was observed.
3.3. In Vitro Cytocompatibility Assessment. The results of the
cytocompatibility assay are described in Figure 7. The values
obtained are in Table S2, and the statistical differences
identified are described in Table S3.
Table 2: Ct, ΔCt, ΔΔCt, and RQ values for all genes under study for OM-MSCs undifferentiated and after neurogenic differentiation.
N= normal; ↑= upregulated; ↓= downregulated; nd = nondefined.
Target gene
Undifferentiated Differentiated
Ct average ΔCt Ct average ΔCt ΔΔCt RQ Regulation
Aldh1l1 36:5 ± 0:4 13.1 32:8 ± 0:3 7.4 -5.7 51.9 ↑
Ascl1 38:6 ± 1:8 15.2 39:5 ± 0:7 14.1 -1.1 2.2 ↑
Cd40 38:7 ± 0:7 15.4 35:1 ± 1:0 9.6 -5.7 53.2 ↑
Cdh2 30:1 ± 0:4 6.8 30:1 ± 0:6 4.7 -2.1 4.2 ↑
Cdk5r1 36:4 ± 0:8 13.0 36:3 ± 1:3 10.9 -2.2 4.5 ↑
Cript 26:9 ± 0:2 3.5 26:5 ± 0:4 1.0 -2.5 5.6 ↑
Cspg4 28:5 ± 0:3 5.1 29:9 ± 0:2 4.4 -0.7 1.6 Ν
Dcx nd nd 39:1 ± 0:0 13.6 nd nd nd
Gap43 37:7 ± 1:1 14.3 39.1± 1.9 13.6 -0.7 1.6 N
Gfap 36:3 ± 0:8 12.9 36:9 ± 0:3 11.5 -1.4 2.6 ↑
Map2 31:5 ± 0:2 8.1 30:5 ± 0:4 5.1 -3.0 8.2 ↑
Mpz nd nd nd nd nd nd nd
Ncam 34:9 ± 0:9 11.4 35:6 ± 2:0 10.2 -1.2 2.3 ↑
Nes 33:0 ± 0:2 9.6 33:6 ± 0:4 8.2 -1.4 2.7 ↑
Neurod1 36:3 ± 0:2 12.9 38:4 ± 1:9 12.9 0.0 0.1 N
Ocln 37:6 ± 1:2 14.3 nd nd nd nd nd
Olig3 40:7 ± 0:0 17.3 nd nd nd nd nd
Rbfox3 nd nd 37:7 ± 0:0 12.3 nd nd nd
Sox10 36:8 ± 1:6 13.4 37:2 ± 1:8 11.8 -1.6 3.0 ↑
Sox2 36:3 ± 0:0 12.9 36:1 ± 0:0 10.7 -2.2 4.7 ↑
Syp nd nd 36:4 ± 1:2 11.0 nd nd nd
















































































Figure 5: ΔCt values for the different genes under study in OM-MSCs undifferentiated and after neurogenic differentiation. Higher delta-CT
values represent lower expression. Results are presented as mean ± SEM.
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At 24h, OM-MSCs seeded only with basal medium (pos-
itive control) showed a clearly higher viability, with statistical
differences with groups (p < 0:0001). The group supple-
mented with DMSO is, as expected, the one with the lowest
viability in this time point, the position that it occupies in
all time points until the end of the assay. At 72 hours, the
groups in which OM-MSCs were seeded in contact with
Reaxon® NGCs and on Matrigel® showed a metabolic activ-
ity superior to that of the positive control, with no statistical
differences between these two groups, but with the group
with Matrigel® showing statistical differences with the posi-
tive control (p = 0:0236). From this time point, the remaining
three groups have very close viability values, and while at
120 h, there are still statistical differences between the posi-
tive control and the group with Matrigel® (p = 0:0021) and
at 168 and 216h, there are no longer differences. Overall, in
the positive control, good viability was observed as early as
24 h, with a progressive increase over time; in the test groups,
there seems to have been an initial delay in metabolic activity
rate related to the presence of the biomaterial and Matrigel®,
a delay that was quickly overcome with a progressive increase
in viability over the different time points. For these three
groups, the plateau seems to have been reached at 120 h, with
reduced increments thereafter. As expected, supplementa-
tion with DMSO was shown to be harmful to the cells right
from the initial time points.
3.4. Scanning Electron Microscopy Analysis. The evaluation of
the samples through SEM allowed observing the external and
internal architecture of the Reaxon® NGCs (Figures 8(a)–
8(c)), the morphology of OM-MSCs (Figures 8(d)–8(f)),
and also the suitability of the biomaterial for cellular adhe-
sion and proliferation, both individually and in homoge-
neous cell layers (Figure 9(a)). The EDS analysis allowed
confirming the presence of cells and homogeneous cell layers,
namely, through the identification of nitrogen (Figures 9(b)–
9(d)).
3.5. Functional Assessment
3.5.1. Motor Performance. The percentage of functional defi-
cit (%) recorded until week 20 is shown in Figure 10. The
complete values of functional deficit can be found in
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Figure 6: Immunolabeling of rat brain tissue (control) and of undifferentiated and differentiated OM-MSCs (P6). Magnifications: 100x
(control) and 400x (OM-MSCs): (a) positive immunoexpression of the intermediate filaments of the astroglial cells; (b) (+) the black
arrow highlights weak cytoplasm immunoreactivity; (c) (+++) the black arrow highlights strong cytoplasm immunoreactivity; (d) positive
immunoexpression of neuronal nuclei; (e (0), f (+)) the black arrow highlights weak cytoplasm immunoreactivity; the grey arrow also
highlights nuclear immunopositivity; (g) positive neuronal membrane and periplasmic immunoreactivity; (h (0), i (++)) the black arrow
highlights moderate membranous immunoreactivity. The inserts highlight the immunoexpression of each marker.
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After neurotmesis injury, a significant loss in hind limb
strength and derived percentage of motor deficit were
observed in all intervened groups. At week 1 postinjury, high
deficit percentages were observed in all groups when com-
pared to the UC group (p < 0:0001). Deficits gradually
declined over the weeks, with variations in the position of
the group with better results in each time point. From the
fourteenth week onwards, a marked decrease in motor deficit
was observed in almost all groups, except for the EtE group,
where the variations up to the end of the study period were
not so evident. After 20 weeks, the ROM group showed the
lowest percentage of motor deficit, presenting statistically
significant differences only with the EtE group (p < 0:0001).
The EtE group was the one with the worst motor perfor-
mance at the end of study time, showing statistically signifi-
cant differences with all the other groups: R (p = 0:0045),
EtER (p = 0:0024), and EtEROM (p = 0:0006). In either case,
the motor deficit percentages were still severe in all inter-
vened groups after 20 weeks, with statistically significant dif-
ferences of all groups compared to the UC group (p = 0:0097
for ROM, p = 0:0006 for EtEROM, and p < 0:0001 for all
other groups).
3.5.2. Nociceptive Function. The WRL values, in seconds,
obtained over the 20 weeks are shown in Figure 11. The com-
plete WRL values can be found in Table S6, and the statistical
differences observed in T20 in Table S7.
After the neurotmesis injury, an increase in WRL time
was observed for all the intervened groups. At week 1 postin-
jury, all experimental groups showedWRL times equal to the
maximum value considered (12 seconds), with the need to
remove the paw from contact with the heating plate to avoid
thermal burns. At this point, no statistical differences were
observed between the experimental groups, but between
these and the UC group (p < 0:0001). From week 2 onwards,
a decrease in WRL time began to be observed for all experi-
mental groups. The EtE group had a much less pronounced
decline in the WRL times, and in week 20, it ended up with
a much higher value than the UC group (p < 0:0001) and
other experimental groups (p < 0:0001). At 20 weeks, the
group with the lowest WRL value was the EtER, but without
significant statistical differences with the other experimental
groups. In addition, excluding the EtE group, the remaining
ones did not show statistical differences with the UC group.
3.5.3. Walking Track Analysis. The observed SFI values are
shown in Figure 12. The complete SFI values can be found
in Table S8, and the statistical differences observed in T20
in Table S9.
After the neurotmesis injury, a severe hind limb impair-
ment was observed in all the intervened groups. In week 1
after the injury, despite the deficits observed in all groups,
the EtE group showed the worst results, a position that
remained until the end of the study period. At this point, sta-
tistically significant differences were observed between all
therapeutic groups and the UC group (p < 0:0001) and also
between the EtE and EtER (p = 0:0007), ROM (p = 0:0019),
and EtEROM (p = 0:0003). From weeks 2-4, an increase in
SFI values began to be observed, improvements that have
remained consistently throughout the 20 weeks of study. In
week 20, the ROM group recorded the best SFI value, but
without statistical differences with the other therapeutic
groups. The UC group showed statistical differences with











































































































Figure 7: Corrected absorbance of the different groups assessed by the PrestoBlue® viability assay, in different time points. Results are
presented as mean ± SEM.
13Stem Cells International
but no statistical differences with the groups ROM and
EtEROM.
The recorded SSI values are shown in Figure 13. The
complete SFI values can be found in Table S10, and the
statistical differences observed in T20 in Table S11.
Expectably, the graphical evolution regarding SSI is iden-
tical to SFI, confirming the effectiveness of the video and
photographic recording method in capturing the perfor-
mance of animals in the walking track analysis. At week 20,
the EtE group is also the one with the worst functional result,
with statistical differences with the ROM group (p = 0:0339).
The ROM group was the one that presented the best result,
only with statistical differences with the EtE group. The UC
group showed statistical differences with EtE (p < 0:0001),
R (p = 0:0058), and EtER (p = 0:0421) but no differences with
EtEROM and ROM.
3.5.4. Kinematic Analysis. The results of the kinematic
evaluation are shown in Figure 14.
The gait pattern of the ankle joint in the sagittal plane sig-
nificantly differed between the four intervened groups and
UC. The 4 groups showed an increased θ° at least during
the entire stance phase (p < 0:001 with UC). The main differ-
ences between therapeutic groups and UC waveforms were
found in the swing phase. In the late swing phase, the 4
groups presented significant differences with the UC group
(p = 0:013 with R, p = 0:011 with EtER, p = 0:013 with




Figure 8: SEM images of the Reaxon® NGC and OM-MSCs: (a) Reaxon® NGC, magnification: 100x; (b) external surface of Reaxon® NGC,
magnification: 100x; (c) inner surface of Reaxon® NGC, magnification: 500x; (d) OM-MSC adhered to the inner surface of the Reaxon® NGC,
magnification: 2000x; (e) OM-MSCs adhered to the inner surface of the Reaxon® NGC, magnification: 5000x; (f) OM-MSC adhered to the
inner surface of the Reaxon® NGC, magnification: 10000x.
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EtEROM presented no differences with the UC group during
the middle swing phase (75-95% of the gait cycle), while
groups R and ROM were significantly different from the
UC group in this same time period (p = 0:006 and p = 0:002,
respectively), revealing a marked plantarflexed joint position.
Regarding the spatiotemporal parameters of the gait, all
groups presented longer cycle times, with an increased stance
phase (UC= 0:244 ± 0:125ms, R = 0:871 ± 0:313ms, EtER =
0:702 ± 0:320ms, ROM= 0:395 ± 0:133ms, and EtEROM=
0:506 ± 0:175ms) and swing phase (UC= 0:131 ± 0:009ms,
R = 0:283 ± 0:036ms, EtER = 0:245 ± 0:054ms, ROM=
0:306 ± 0:046ms, and EtEROM= 0:344 ± 0:070ms).
Table 3 contains a qualitative representation of the per-
formance of the therapeutic groups in the different essays
and tests performed in vivo. In general, it is possible to see
that the groups that received OM-MSCs and NGCs had a
better overall performance, with good results in basically all
parameters. However, the results are not regular, and in
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(d)
Figure 9: SEM and EDS evaluation of the Reaxon® NGC and OM-MSCs: (a) OM-MSC cell layer adhered to the inner face of the Reaxon®
NGC, magnification: 10000x; (b) EDS evaluation of the Z1 region-OM-MSCs; (c) EDS evaluation of the Z2 region-OM-MSC cell layer;
(d) EDS evaluation of the Z3 region-inner surface of the Reaxon® NGC without a cell layer.
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Figure 10: Values of motor deficit (%) over the 20 weeks of the recovery period. Results are presented as mean ± SEM.
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3.6. Stereological and Histomorphometric Analysis
3.6.1. Nerve Stereological Analysis. The results obtained in the
stereological evaluation are shown in Figure 15. The corre-
sponding stereological images can be seen in Figure 16.
The total stereological results obtained can be found in
Table S12, and the statistical differences observed are in
Table S13.
All the therapeutic options considered demonstrated ste-
reological evidence of nerve fiber regeneration. When com-
pared to the control, after 20 weeks, the nerves submitted to
different therapeutic options showed microfasciculation phe-
nomena with axons and fibers of smaller diameter, higher
density and number of nerve fibers, and thinner myelin
sheaths. The therapeutic groups never showed statistical dif-
ferences between them in any parameter. In the parameters
density and number of fibers, the EtE group presented the
highest value (30072 ± 5443 fibers/mm2 and 17423 ± 2217
fibers, respectively). In density and axon diameter, there are
statistically significant differences between UC and all the
other groups (p < 0:0001); in the total number of fibers, there
are differences between UC and EtE (p = 0:0327).
The highest value of nerve fibers and axon diameter was
observed in the EtER group (4:08 ± 0:33μm and 2:53 ± 0:18,
respectively), and UC presents differences with all therapeutic
groups (p < 0:0001). In the thickness of the myelin sheath, the
highest value is that of the EtER group (0:78 ± 0:08μ) and
again UC has statistical differences with all other groups
(p < 0:0001). The largest cross-sectional area was reached in
the EtEROM group (0:6917 ± 0:2441mm2), and UC pre-
sented statistical differences with all groups (p = 0:0337 with
EtE, p = 0:0331 with R, p = 0:0105 with EtER, and p = 0:0436
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Figure 11: WRL values (s) over the 20-week recovery period. Results are presented as mean ± SEM.
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Figure 12: Functional assessment (SFI) over the 20-week recovery period. Results are presented as mean ± SEM.
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with ROM) except EtEROM (data not shown). Regarding the
g-ratio, the group with the highest value was the EtE
(0:60 ± 0:01).
3.6.2. Histomorphometric Muscle Analysis. All cranial tibial
muscles associated with sciatic nerve injury had lower final
weights than the corresponding contralateral muscles at the
time of collection, with an average loss of 35:05 ± 4:69%.
The highest percentage of loss was observed in group R
(42:57 ± 10:60%), and the smallest in the ROM group
(30:94 ± 14:07%).
The values of the fiber area and minimum Feret’s
diameter resulting from the evaluation of the cranial tibial
muscles are shown in Figures 17(a) and 17(b), and the
histological images of the different groups can be seen in
Figure 18. The statistical differences observed are found
in Table S14.
Regarding the fiber area, the therapeutic groups with the
best results were EtE (2510:91 ± 23:08 μm2) and ROM
(2483:38 ± 35:91 μm2). The EtE group did not show
statistically significant differences with the UC group
(2634:79 ± 24:01 μm2), unlike ROM (p = 0:0438). The EtE
group showed statistical differences with the groups R
(p = 0:0003) and EtER (p < 0:0001), as well as ROM (R
(p = 0:0004) and EtER (p < 0:0001)). The worst result was
observed in the EtER group (2182:484 ± 18:41 μm2), which
only shows no statistically significant differences with the R
group (2250:50 ± 18:57 μm2), the second with the worst
outcome (p = 0:0438 with EtEROM). The R group did not
show statistical differences with the EtEROM group
(2366:69 + 1992 μm2). Excluding the EtE group, the UC group
presented statistically significant differences with all other ther-
apeutic groups (R, EtER (p < 0:0001); EtEROM (p = 0:0010)).
In the case of the minimum Feret’s angle, the best values
were also observed in the EtE (47:42 ± 0:23μm) and ROM
(46:87 ± 0:23μm) groups, but in this case, the UC
(49:43 ± 0:25μm) group showed statistically significant differ-
ences with all therapeutic groups (p < 0:0001). The EtE group
did not differ statistically from ROM, unlike with other groups
(R and EtER (p < 0:0001); EtEROM (p = 0:0154)); The ROM
group differs statistically from the R and EtER groups
(p < 0:0001). The worst outcome was observed in group R
(44:37 ± 0:15μm), followed by EtER (45:15 ± 0:22μm) with
w5hich it has statistical differences (p = 0:0272). The EtEROM
(46:38 ± 0:25μm) group also presents statistically significant
differences with the two worst groups, R (p < 0:0001) and
EtER (p = 0:0098).
4. Discussion
The success resulting from the repair of a peripheral nerve
after PNI depends on the type and extent of the injury. In
neurotmesis injuries, the most severe, the complete transec-
tion of the nerve culminates in the loss of continuity and
function, axonal and structural disorganization, and loss of
the coating elements and myelin sheath [78]. The use of
NGCs is a valid alternative to traditional techniques for treat-
ing neurotmesis injuries such as EtE sutures and autographs,
ensuring the maintenance of a proregenerative environment
within it and less influenced by the organic immune response
that has, sometimes, detrimental effects [79]. These NGCs
can consist of materials with natural and artificial origin,
and their chemical and physical characteristics can be modi-
fied and adapted to ensure the best performance in promot-
ing nerve regeneration and controlling inflammatory
reaction [80]. However, despite the various materials pro-
posed so far, none yet guarantee an optimal functional recov-
ery after conduit application. The current most promising
options include modifying the NGCs’ inner architecture,
transplanting MSCS to its lumen, and also including ECM
and neurotrophic factors in the therapeutic approach. In fact,
the nerve regeneration promoted in this work, using a com-
bination of chitosan NGCs and OM-MSCs suspended in
Matrigel®, allowed observing good functional, kinematic,
and histomorphometric outcomes in animals subjected to
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Figure 13: Functional assessment (SSI) over the 20-week recovery period. Results are presented as mean ± SEM.
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Table 3: Qualitative general classification of the performance of the therapeutic groups in the tests and essays carried out in vivo. The groups
were classified according to the statistical differences observed between them and the UC group: ∗∗∗∗ (-); ∗∗∗ (±); ∗∗, ∗ (+); and no
statistical differences (++).
EtE R EtER ROM EtEROM
Functional assessment
EPT - - - + ±
WRL - ++ ++ ++ ++
SFI - ± + ++ ++
SSI - + + ++ ++
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Figure 14: Kinematic evaluation of rats 20 weeks after neurotmesis: (a) R; (b) EtER; (c) ROM; (d) EtEROM. Upper graphs show the mean θ°
during UC gait (blue) versus the pattern of experimental groups (green) at the level of the ankle joint. Lower graphs show SPM statistic as a
function of the gait cycle. SPM unpaired t-tests were performed, comparing the mean kinematic angle of each pattern to the respective mean
kinematic angle of UC (α = 0:05). The moments of the gait cycle in which the critical threshold (t∗) was exceeded (corresponding to the
moment when the θ° of the experimental groups is superior to the θ° of UC) are represented by the grey area of the lower graphs. G1 =R;
G2 =EtER; G3 =ROM; G4=EtEROM; SPM: statistical parametric mapping.
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neurotmesis, although the results are not yet good enough to
equate to complete regeneration.
Chitosan has been used in medical applications for a long
time due to its biodegradability, biocompatibility, and
absence of toxicity. Although this biomaterial has been
applied in various forms and with different surgical tech-
niques, the number of works where it has been used as NGCs
is reduced, particularly as NGCs consisting solely of chitosan
[16]. One work that studied the benefits of applying Reaxon®
NGCs in the primary repair of peripheral sensory nerves
demonstrated better outcomes of tactile gnosis and sensitiv-
ity than the traditional EtE suture technique [21]. Another
work explored the application of fresh skeletal muscle fibers
in combination with Reaxon® conduits to promote the
regeneration of the rat median nerve after neurotmesis. How-
ever, although this combined technique seems to have advan-
tages, namely, with an increased production of neuregulin,
the observation of no statistical differences with the remain-
ing therapeutic groups in terms of functional recovery and
morphometric analyses did not allow drawing any broader
conclusions [81]. In this work, Reaxon® NGCs with 2.1mm
internal diameter were used in different surgical techniques
to stimulate rat sciatic nerve regeneration after neurotmesis,
both alone and in combination with OM-MSCs and
Matrigel®.
OM-MSCs have only recently begun to be explored in
regenerative medicine and applied to the nervous system.
In a study that compared the use of biphasic collagen and
laminin-functionalized hyaluronic acid NGCs with and
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Figure 15: Results of the stereological assessment of sciatic nerve fibers 20 weeks after neurotmesis: (a) density; (b) total number of fibers;
(c) axon diameter; (d) fiber diameter; (e) myelin thickness; (f) g-ratio. Results are presented as mean ± SEM.
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technique revealed better clinical and electrophysiological
outcomes than the use of NGCs alone, with a greater number
of axons and a more rapid return of nociceptive withdrawal
reflex to normal values [45]. The use of rat OM-MSCs in this
work follows a wide study of characterization of these cells
[23]. A complete biological characterization was carried
out, with identification of karyotype normality in different
passages, capacity for tridifferentiation and neurogenic dif-
ferentiation, and confirmation of their stemness characteris-
tics, allowing the establishment of these cells as adequate to
be applied therapeutically in regenerative medicine. In addi-
tion, it also allowed identifying several genes characteristic of
MSCs and respective differentiations and also specific surface
markers. A preliminary characterization of the conditioned
medium of the OM-MSCs at 48h also allowed identifying
immunomodulatory and immunosuppressive factors, che-
mokines, growth factors, and interleukins important in
regenerative phenomena, complementing findings identified
by other authors [82]. Since in this previous study the genes
and surface markers associated with the potential for neuro-
genic differentiation were identified in OM-MSCs in their
undifferentiated state and the capacity for neurogenic differ-
entiation was tested exclusively by observing the acquisition
of neuroglial-like shape in culture, in the present study, an
additional biological characterization was carried out to
identify genes and surface markers related to neurogenic
differentiation, comparing their presence and expression
between undifferentiated cells and after neurogenic differen-
tiation. Prior to its in vivo application, the cytocompatibility
between OM-MSCs and Reaxon® and between cells and
Matrigel® was tested, to ensure that cell viability and metab-
olism would not be adversely affected by the contact between
cells and the biomaterial and ECM substitute. Additionally,













Figure 16: Light micrographs of toluidine blue-stained sciatic nerve semithin sections for the different groups: (a) UC; (b) EtE; (c) R;
(d) EtER; (e) ROM; (f) EtEROM.
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OM-MSCs were analyzed by SEM and EDS to confirm the
adhesion of these cells to their internal surface without mor-
phological changes and with the formation of homogeneous
cell layers. After these preliminary tests, finally the chitosan
NGCs combined with OM-MSCs and Matrigel® were used
in the sciatic nerve of rats after neurotmesis lesions, testing
the capacity of this therapeutic approach to stimulate periph-
eral nerve regeneration after PNI. This capacity was tested
in vivo by functional and kinematic studies and postmortem
through histomorphometric and stereological evaluation.
With the RT-PCR technique, 22 genes associated with
neurogenic differentiation were quantified in undifferenti-
ated and differentiated OM-MSCs. It was also possible to
identify changes in the fold expression of these genes between
cells of the two groups. In both groups, cells in P6 were used,
according to the increased propensity of the cells to differen-
tiate in this passage, as previously identified [23]. The
absence of contamination in the RNA sample used for cDNA
synthesis was confirmed by spectrophotometry, and the
interpretation of the melting curves confirmed the presence
of a single peak, that is, amplification of a single amplicon
for each gene. The identification of genes characteristic of
neuroglial cells in undifferentiated cells must be interpreted
as a propensity for these cells to follow neurogenic differenti-
ation when subjected to the appropriate prodifferentiation
stimuli. In the differentiated cells, the presence of genes can
already be considered having an active function in their spe-
cific functions and acquired phenotypes. The MPZ gene,
expressed specifically in the Schwann cells of the peripheral
nervous system and responsible for a transmembrane glyco-
protein with structural function in the peripheral myelin
sheath [83], was the only one not identified in any of the cell
groups. The Dcx (microtubule-associated phosphoprotein
expressed in immature postmitotic neurons, required for
neuronal migration [84]), Rbfox3 (specific protein from
mature postmitotic neurons [85]), and Syp (regulation of
vesicular endocytosis during the synapse of mature neurons
[86]) genes were identified in the differentiated cells but not
in the undifferentiated ones, which may indicate a differenti-
ation of OM-MSCs in a neuron-like direction. It is important
to note that synaptophysin has been previously identified in
undifferentiated OM-MSCs through immunohistochemistry
techniques, although with weak immunoreactivity [23]. Ocln
(expressed in neuroepithelial cells in precocious stages of
neurogenesis [87]) was only expressed in the undifferentiated
cells, being absent as expected in the differentiated cells.
Olig3, expressed in mature oligodendrocytes [88], was also
only expressed in undifferentiated cells. All the remaining
genes were identified in the two groups of cells, in no case
with downregulation in the differentiated cells. The genes
with the highest RQ value were Aldh1l1 (astrocytic differen-
tiation marker [89]) and Cd40 (expressed in microglia [90]),
that is, genes associated with glial cells in the central nervous
system. Other genes associated with glial cells upregulated in
differentiated OM-MSCs include Cdh2 (expressed in radial
glia [91]), GFAP (fibrillary protein characteristic of glial cells
expressed in astrocytes and radial glia [92]), Ncam1 (glyco-
protein related to cell adhesion in nonmyelinating Schwann
cells [93]), Nes (intermediate filament protein expressed in
the undifferentiated central nervous system, in radial glia
before the development of astrocytes, but also in the mature
central nervous system [94]), Sox2 (persistent marker for
multipotential neural stem cells expressed in proliferating
cells and those that follow glial differentiation, but not
expressed in postmitotic neurons [95]), and Sox10 (present
in neuroepithelial cells and myelinating Schwann cell precur-
sors [96]). GFAP and Sox2 have also been previously identi-
fied in undifferentiated OM-MSCs [23]. In turn, genes
associated with neurons, upregulated, include Ascl1 (pro-
moting neural differentiation, namely, in the generation of
olfactory neurons [97]), Cdksr1 (different functions from
neuronal differentiation and migration to synaptic transmis-
sion [98]), Cript (postsynaptic protein in excitatory synapses
[99]), Map2 (microtubule stabilizer in the dendrites of post-
mitotic neurons [100]), and Tubb3 (immature neuron-
specific tubulin also involved in peripheral axon regeneration
[101]. Finally, the Cspg4 (associated with myelinating oligo-









































Figure 17: Histomorphometric analysis of cranial tibial muscle: (a) individual fiber area; (b) minimum Feret’s diameter of the muscle fibers.
Results are presented as mean ± SEM.
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found in neurons undergoing differentiation, being highly
expressed in neurons in development or in regeneration
during axonal growth, also expressed in nonmyelinating
Schwann cells [103, 104]), and Neurod1 (associated with
immature neurons, promoting neural development, and
inducing terminal neuronal differentiation in olfactory neu-
rogenesis [105]), although expressed in both groups of cells,
are neither up- nor downregulated in the differentiated
OM-MSCs. In general, the results of RT-PCR show that
when undergoing neurogenic differentiation, OM-MSCs
not only acquire a neuroglial cell phenotype but also present
significant upregulation of neuroglial genes.
To complement the results obtained in the RT-PCR, an
immunohistochemical evaluation was performed to identify
the GFAP, NeuN (Rbfox3), and GAP43 protein immunomar-
kers. The GFAP marker was identified in both undifferenti-
ated and differentiated cells, but with weak and strong
immunoreactivity in the first group and after neurodifferentia-
tion, respectively. This result corroborates that obtained in the
RT-PCR in which upregulation of GFAP was detected among
the differentiated cells. GFAP had previously been identified in
undifferentiatedOM-MSCs [23]. NeuN expression was identi-
fied only in neurodifferentiated cells with weak immunoreac-
tivity, and in RT-PCR, Rbfox3 expression was also only
observed in cells after differentiation. GAP43 was expressed
only on the membrane of differentiated cells, with moderate
reactivity. In RT-PCR, although GAP43 was identified in both
groups of cells, neither upregulation nor downregulation was
observed after neurodifferentiation.
The RT-PCR and immunohistochemistry assays followed
the same line of results, demonstrating an overexpression




Figure 18: Histological images of the cranial tibial muscles subjected to histomorphometric analysis in the different groups: (a) UC; (b) EtE;
(c) R; (d) EtER; (e) ROM; (f) EtEROM. H&E, magnifications: 100x.
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differentiation of cells. However, since upregulation and
immunoreactivity of both neuron-related and glia-
associated genes and protein markers were noticed, it is dif-
ficult to define whether there is a predominant tendency for
OM-MSCs to differentiate into some specific neuroglial cell
type. Probably, in vivo, OM-MSCs will follow different lines
of neural or glial differentiation depending on the implanta-
tion site and the local stimuli that they receive.
The application of biomaterials in the human body or in
animal models must obligatorily follow certain requirements:
being biologically safe (without toxic effects and without gen-
erating immune reactions in the host), biofunctional, and
resistant to degradation (excluding biodegradation intrinsic
to the material). These characteristics can be confirmed by
determining their biocompatibility [106]. The term cytocom-
patibility, that is, the in vitro behavior and metabolic
performance of specific cells when seeded in contact with a
material, can be considered a particular case of biocompati-
bility, which is the wider term [107]. The cytocompatibility
between OM-MSCs and Reaxon® and Matrigel® was studied
using a PrestoBlue® cell viability assay. PrestoBlue® is a blue
reagent based on resazurin, for which cell membranes are
permeable, which is metabolized at the mitochondria, result-
ing in resorufin, a red fluorescent compound that can be
measured both visually and through its absorbance, estab-
lishing a direct relationship with the viability and metabolic
activity of the studied cells [108]. The results of this assay
revealed that the presence of chitosan conduits andMatrigel®
temporarily delayed cell adhesion, with differences in viabil-
ity and metabolic performance being observed at 24h com-
pared to OM-MSCs that were seeded only with the usual
culture medium. However, from this point on, the viability
associated with the biomaterial and Matrigel® increased,
and for later time points, there were no differences between
the positive control and the test groups. To confirm the
microscopic interaction between OM-MSCs and Reaxon®
conduits, the chitosan tubes on which the cells were seeded
were evaluated by SEM and EDS, an evaluation in which it
was possible to confirm the permissible characteristics of
Reaxon®. OM-MSCs adhered to the internal surface of the
conduits, maintaining their normal morphology and forming
cell layers. The EDS technique, when used in combination
with SEM, allows the identification of the elements present
near the sample surface to be analyzed, creating a graphic
map of the chemical components identified through the
energy of the emitted X-rays [109]. In this case, in all the ana-
lyzed regions, it is possible to see the predominance of the
elements carbon and oxygen, due to the chemical constitu-
tion of chitosan. However, the evaluation of the Z1 and Z2
regions allows the identification of nitrogen peaks, which,
being a fundamental cellular chemical component, works
here as an identifier for the presence of cell material adhering
to the surfaces of the NGC, confirming that the structures
identified in the SEM are, in fact, OM-MSCs and cell layers
adhering to the internal surface of the chitosan NGC.
After the additional biological characterization of OM-
MSCs and the determination of the cytocompatibility
between MSCs, Reaxon®, and Matrigel®, the efficacy of the
chosen therapeutic combinations in vivo was evaluated. After
surgical application of the five therapeutic options, the ani-
mals were regularly evaluated over 20 weeks to determine
the progression of motor, nociceptive, and behavioral perfor-
mance and gait characteristics. At the end of the study
period, the animals were subjected to a kinematic evaluation
and the sciatic nerves and cranial tibial muscles were col-
lected for stereological and histomorphometric evaluation,
respectively.
The percentage of motor deficit decreased significantly in
all animals during the first weeks after neurotmesis. Between
the sixth and eighth week, an improvement in motor perfor-
mance began to be observed in all groups, but it is from the
fourteenth week that this improvement becomes more evi-
dent, indicating superior motor nerve fiber regeneration. At
20 weeks, all groups had a percentage of motor deficits much
lower than the postsurgery values, revealing the efficacy of all
therapeutic approaches in promoting the recovery of motor
function. The ROM group was the one with the best results.
With the exception of the EtE group, the one with the worst
outcome, there were no statistical differences between the
groups under test, but in none of them, a motor performance
similar to that of the control group was achieved.
The WRL also increased to the maximum value consid-
ered after neurotmesis (12 s), indicating the total absence of
thermal sensitivity in this phase. Between the second and
the fourth week after surgery, a decrease in WRL time was
observed, indicating a regeneration of sensory nerve fibers.
This improvement, less marked in the EtE group, continued
until the end of 20 weeks. The best outcome was observed
in the EtER group, but the values of all study groups were
low enough to not observe statistical differences between
them and the UC group. These good results in nociceptive
assessment corroborate those observed in other studies using
Reaxon® NGCs [21] and OM-MSCs [45].
The observed results of SSI and SFI are concordant. In
both cases, after neurotmesis, the values fell close to the min-
imum values considered after injury. Between the second and
the fourth week, there was an improvement in the values of
both indexes, values that increased continuously until the
end of the 20 weeks. The EtE group was, again, the one with
the worst outcome, and the ROM and EtEROM groups were
the ones with the best results, without statistical differences
with the UC group. Only the groups that did not receive
OM-MSCs and Reaxon® showed statistical differences with
UC. The videographic and photographic recording technique
used in this work also made it possible to replace the tradi-
tional technique of recording footprints with ink, making
the process faster and easier to perform and the results easier
to interpret.
Overall, it is possible to state that all the therapeutic groups
promoted improvements in the functional parameters evalu-
ated, with the groups receiving OM-MSCs, Reaxon®, and
Matrigel® promoting the best final results in motor perfor-
mance and walking tract analysis and the EtER group promot-
ing the best nociceptive recovery. The nociception and sciatic
index final values were good enough to avoid statistical differ-
ences between groups with better outcomes and control
groups, the fact that was not registered in the motor recovery.
The EtE group showed the worst performance in all tests.
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Regarding the kinematic results, an alternative statistical
strategy was applied using global variables for curve align-
ment, reducing individual joint data to overcome the joint
kinematic interanimal variability after peripheral nerve
lesions, as proposed in previous works [110–112]. It was pos-
sible to measure the movement deficits of the ankle joint after
PNI and verify the severity during the swing phase of walk-
ing. It is during the swing phase, instead of during the stance
phase, that motion dysfunction is more evident after sciatic
nerve denervation [112]. EtER and EtEROM revealed a sim-
ilar pattern in terms of gait deviations when compared with
the UC group, especially during the swing phase, with the
EtEROM group presenting the best performance among the
therapeutic groups. These two groups have in common the
fact that both sciatic nerves have been subjected to an EtE
suture associated with therapeutic intervention with NGC
and OM-MSCs, but considering the poor results observed
in the EtE group in the functional assessment and also the
results of the kinematic evaluation obtained in previous stud-
ies [113], the influence of this traditional suture on this good
kinematic performance should be interpreted with caution.
The ROM group was the one that showed the worst results
in the kinematic evaluation, an unexpected result considering
the good performance of this group in almost all other tests.
Ankle motion deficits affecting the swing phase demonstrate
the lack of ability of intervened animals to actively perform
dorsiflexion and plantarflexion. A decreased ankle dorsi-
flexion angle at the midswing, defined as the instant where
the swinging leg crosses the contralateral hind limb, has
already been reported after sciatic nerve axonotmesis
[112, 114, 115], and it is also observed in this case, even
in animals belonging to groups with better recovery and
kinematic performance. Although the contractures observed
in most animals immediately after the neurotmesis lesion are
attenuated over time, functional recovery is not complete,
and after twenty weeks, there are still kinematic indications
of dysfunctions in gait and its components/phases. Conse-
quently, the duration of the stance phase and the swing
phase is longer than the times considered standard for the
rat [116].
The analysis and quantitative estimation of nerve fiber
morphology are an essential assessment in determining the
degree of nerve regeneration after injury and treatment,
and stereology should always be interpreted in combination
with functional and kinematic results [75]. In this work, all
nerves that suffered neurotmesis and had been subjected to
specific therapies presented, after 20 weeks, microfascicula-
tion, high density and number of nerve fibers, axons with
small diameter, and thin myelin sheaths, characteristics nor-
mally observed in nerves that have undergone a regeneration
process. The corresponding images in Figure 16 corroborate
the stereological findings. The results obtained in this analy-
sis must, however, be evaluated with extra care. The number
and density of nerve fibers are often interpreted as direct
indicators of nerve regeneration. A high number of regener-
ated nerve fibers can be associated not only with a good
regenerative process but also with changes such as aberrant
sprouting, and a high density can also reflect the presence
of a large number of axons, but of small dimensions. Con-
versely, a lower fiber density may represent the presence of
larger axons but also the presence of intraneural edema. Usu-
ally, shortly after the nerve injury, the tendency is to see an
increase in the number and density of nerve fibers and axons
of smaller diameter during nerve regeneration, a situation
that is reversed over time, when the axons tend to increase
their diameter and the number and density may decrease
[117]. The EtE group was the one that presented higher
values of density and number of fibers, being therefore, and
considering the results of the functional assessment, the one
that is in a less advanced phase of nerve regeneration after
twenty weeks. EtEROM and EtER had the lowest values of
density, and EtER the lowest number of fibers. The diameter
of the nerve fiber is the main determinant of conduction
velocity since it informs about the axonal diameter and the
thickness of the myelin sheath [118]. For the three parame-
ters, d, D, and M, the EtER group is the one that presents
the best stereological performance, but the fact that its values
are very different from those observed in the UC group and
that there are no statistical differences between the thera-
peutic groups does not allow more extended conclusions.
The g-ratio relates the axonal diameter to the total diam-
eter of the nerve fiber (d/D) and is commonly analyzed
as a functional and structural index that reflects the qual-
ity of the axonal myelination. Traditionally, the value of
0.6 was established as the optimal g-ratio for peripheral
nerves [119, 120]. Consequently, deviations in the thick-
ness of the myelin sheaths, and therefore g-ratios bigger
or smaller than 0.6, promote a decrease in conduction
speeds [121]. The g-ratio observed in this work reveal
values of 0.6 or very close for all groups (UC and thera-
peutic groups) and, therefore, with no statistical differences
observed. This result seems to indicate that, despite the ste-
reological differences observed in the therapeutic groups,
the interventional nerves developed good axonal myelination
and potential for efficient conduction speeds, which corrobo-
rates the results observed in the remaining performed tests.
Overall, the stereological assessment of the intervened nerves
reveals a stimulation of nerve regeneration and identical per-
formances among all the therapeutic groups tested. However,
the absence of statistical differences between the groups con-
sidered and the fact that the final values fall below those
observed in the control group for almost all parameters do
not allow establishing any therapeutic option as the most
advantageous.
Histomorphometric assessment of the anterior tibial mus-
cle, as an effector muscle of the sciatic nerve, revealed different
neurogenic muscle atrophies depending on the therapeutic
approach. The best final values of the fiber area and minimum
Feret’s angle were observed in the EtE group, in the first case
without statistical differences with the control group, results
that deviate from the poor performance of this surgical
approach in the remaining evaluations. In both cases, the
ROM group was the second with the best muscle parameters
and was also the one where the percentage of muscle mass loss
was lower, corroborating the good performance of this thera-
peutic option in the functional evaluation. The groups where
the biomaterial was used alone were those with the worst
results. These outcomes seem to indicate that in the EtE group,
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there was an earlier reestablishment of the nerve connections,
perhaps due to possible factors that temporarily delay cell
activity in other groups, such as t5he presence of biomaterial
and Matrigel® as demonstrated in cytocompatibility assays,
resulting in an also earlier nervous reestimulation of the ante-
rior tibial muscle and avoiding/decreasing neurogenic atro-
phy. Despite this early reconnection, functional recovery in
this group was not as effective as in the remaining therapeutic
groups, and the EtE group showed the worst outcomes than
the other groups in terms of motor and nociceptive recovery
and sciatic indexes. At the end of 20 weeks, the ROM and
EtEROM groups demonstrate a performance similar to EtE,
which may indicate an early reconnection associated with
the use of OM-MSCs that does not seem to have happened
in the groups that only received Reaxon®. It is interesting to
note that ROM and EtEROM groups also showed the best
results in the EPT, SFI, and SSI tests, which confirms the
importance of avoiding/reversing neurogenic muscle atrophy
to maintain a good motor performance and guarantee the
return to a normal behavioral activity during gait.
Excluding in the histomorphometric evaluation of the
cranial tibial muscle, the EtE group presented a poor perfor-
mance in all essays, which can be considered unexpected
since this technique is still considered, together with auto-
grafting, gold standard in the treatment of neurotmesis when
it is possible to obtain a tension-free coaptation and a well-
vascularized bed at the injury site. However, the observation
of weaker therapeutic performance in cases treated with EtE
than in those that received tubulation repair is not exclusive
[122, 123]. Despite the juxtaposition and oriented alignment
of the two nerve tops before the EtE suture, it is very difficult
to guarantee an accurate axon-to-axon or endoneurium-to-
endoneurium perfect alignment and reconnection, which
can often translate into phenomena of misdirection and
establishment of aberrant motor/sensory connections in the
regenerating nerve. On the other hand, it has already been
proven that the use of NGCs manages to mitigate the
phenomena of misdirection [124], and when used in combi-
nation with MSCs, they are capable of promoting a proregen-
erative environment, prolonged over time, which translates
into a better performance of these therapies in relation to
the traditional application of sutures.
Despite the promising results obtained, it is important
to consider some limitations that must be overcome in
future works. The small number of animals used in each
group can limit the extent of the conclusions reached,
and although the rat model is a good starting point, to
explore the therapies studied here in a translational per-
spective, it is important to consider for future essay the
use of models with greater complexity that better mimic
the speed and characteristics of human nerve regeneration,
which differs significantly from that observed in the rat
model [125]. In addition, it will also be important to carry
out other functional assessment tests that consider a
dimension that was not explored here, namely, nervous
and muscular electrophysiological essays that will allow
obtaining important information about the restitution of
the nerve conductivity after regeneration and that were
not evaluated in this work.
5. Conclusions and Further Directions
The combined use of MSCs and biomaterials to promote
peripheral nerve regeneration after PNI is an increasingly
applied therapeutic technique with promising results. OM-
MSCs, despite the few published works, seem to be a type
of MSCs with desirable characteristics to be applied in nerve
regeneration, and the use of chitosan NGCs has proven to be
an effective therapy. In this work, the initial biological
characterization of OM-MSCs allowed confirming through
PCR and immunohistochemistry techniques the tendency
of these cells to follow a neurogenic differentiation, not only
morphologically but also through the expression of neuro-
glial markers. Additionally, both cytocompatibility studies
and its use in different therapeutic groups did not lead to
local reactions or evidence of systemic toxicity associated
with the presence of OM-MSCs, which reinforces the safety
in the therapeutic use of these cells.
The functional assessment, kinematic analysis, and histo-
morphometric evaluations confirmed that the use of Reaxon®
NGCs and OM-MSCs promoted functional improvements
throughout the study period and evidence of nerve regenera-
tion after 20 weeks. The best motor performances and sciatic
indexes were observed in the groups that received both NGCs
and OM-MSCs, ROM and EtEROM, and the nociceptive
function recovered more effectively in the EtER group. Gait
dysfunctions after twenty weeks were less evident in the
EtEROM group. All therapeutic groups had identical stereo-
logical results, although the EtER group showed slightly higher
values in important parameters such as axonal diameter, nerve
fiber diameter, and myelin sheath thickness. The EtE tech-
nique obtained the best results in the histomorphometric eval-
uation of the cranial tibial muscle, but with the ROM and
EtEROM groups showing identical performances.
In conclusion, the results obtained in this work demon-
strate promising effects of the use of OM-MSCs and Reaxon®
NGCs in promoting the regeneration of injured peripheral
nerves and may open new therapeutic paths. However, there
were also irregularities in some results of the different thera-
peutic groups, and in most of the essays, the results obtained
are below those observed in the control group. This scenario
reinforces the fact that nerve regeneration is a complex and
multifactorial process, and to fully understand the regenera-
tive efficacy of the treatments instituted, an integrated
approach is always necessary, using different functional and
histomorphometric assessment techniques that evaluate both
dimensions associated with nerve regeneration: structure and
function. Further studies are necessary to answer the doubts
raised and establish more reasoned therapeutic approaches






EDS: Energy-dispersive X-ray spectroscopy
EEPT: Experimental extended postural thrust
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EPT: Extended postural thrust
EtE: End-to-end suture
EtER: EtE and wrapping with Reaxon® NGC
EtEROM: EtE, wrapping with Reaxon® NGC, and
administration of OM-MSCs suspended in
Matrigel®
HMDS: Hexamethyldisilazane
ITS: Spread distance between toes 2 and 4
MSCs: Mesenchymal stem cells
MSCs: Mesenchymal stem/stromal cell
n: Number of animals per group
NEPT: Normal extended postural thrust;
NGC: Nerve guidance conduit
OM: Olfactory mucosa
OM-MSCs: Olfactory mucosa mesenchymal stem/stromal
cells
PBS: Phosphate-buffered saline solution
PL: Print length
PNI: Peripheral nerve injuries
R: Suture of the nerve ends to the Reaxon® NGC
ROM: Suture of the nerve ends to the Reaxon® NGC
and administration of OM-MSCs suspended in
Matrigel®
RQ: Relative quantification
RT-PCR: Reverse transcriptase polymerase chain reaction
SEM: Scanning electron microscopy
SFI: Sciatic functional index
SPM: Statistical parametric mapping
SSI: Static sciatic index
TS: Spread distance between toes 1 and 5
UC: Uninjured control
WRL: Withdrawal reflex latency.
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Supplementary Materials
Table S1: list of genes under study with the respective
amplicon context sequence, ensemble gene ID, and PCR
product length. Table S2: corrected absorbance in the dif-
ferent groups assessed by the PrestoBlue® viability assay,
in different time points. Results presented as mean ±
SEM. Table S3: statistical differences in the corrected
absorbance identified between different groups: (a) 24 h;
(b) 72h; (c) 120 h; (d) 168 h; (e) 216 h (ns =no statistically
significant differences). Table S4: values of functional defi-
cit (%) obtained performing the EPT test. These tests were
performed preoperatively (T0) and 1 and 2 weeks after
neurotmesis (T1 and T2) and from there every two weeks
until week 20 (T20). Results are presented as mean and
SD (n=number of animals per group). Table S5: statistical
differences observed in the EPT test at 20 weeks (ns =no
statistically significant differences). Table S6: WRL values
in seconds (s) obtained performing the WRL test. These
tests were performed preoperatively (T0) and 1 and 2
weeks after neurotmesis (T1 and T2) and from there every
two weeks until week 20 (T20). Results are presented as
mean and SD (n=number of animals per group). Table
S7: statistical differences observed in the EPT test at 20
weeks (ns =no statistically significant differences). Table
S8: results of functional recovery through the SFI. These
tests were performed preoperatively (T0) and 1 and 2
weeks after neurotmesis (T1 and T2) and from there every
two weeks until week 20 (T20). Results are presented as
mean and SD (n=number of animals per group. Table
S9: statistical differences observed in the SFI test at 20
weeks (ns =no statistically significant differences). Table
S10: results of functional recovery through the SSI. These
tests were performed preoperatively (T0) and 1 and 2
weeks after neurotmesis (T1 and T2) and from there every
two weeks until week 20 (T20). Results are presented as
mean and SD (n=number of animals per group). Table
S11: statistical differences observed in the SSI test at 20
weeks (ns =no statistically significant differences). Table
S12: stereological quantitative assessment. The different
parameters considered were evaluated in the regenerated
sciatic nerve at week 20 (T20) after neurotmesis. Results
are presented as mean and SD (n=number of animals
per group). Table S13: statistical differences in the nerve
stereological analysis: (a) density of fibers; (b) total num-
ber of fibers; (c) axon diameter; (d) fiber diameter; (e)
myelin thickness; (f) g-ratio; (g) cross-sectional area
(ns =no statistically significant differences). Table S14:
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statistically significant differences in the evaluation of the
tibial cranial muscles: (a) individual fiber area; (b) mini-
mum Feret’s diameter of the muscle fibers (ns =no statis-
tically significant differences). (Supplementary Materials)
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